Esketamine use in real-world clinical practice in patients with treatment-resistant depression
Our results suggest that extending the numbers of esketamine administration may increase the chances to obtain remission. Adverse effects did not impact the treatment course.
Authors
- Ezequiel Di Stasio
- Alejandro Porras‐Segovia (ORCID: https://orcid.org/0000-0003-2019-9099)
- Sergio Benavente López
- Ana María de Granda-Beltrán (ORCID: https://orcid.org/0009-0000-6365-0535)
- Ismaël Conejero (ORCID: https://orcid.org/0000-0002-9142-1278)
- Raquel Álvarez-García (ORCID: https://orcid.org/0000-0002-1145-4425)
- Enrique Baca‐García (ORCID: https://orcid.org/0000-0002-6963-6555)
- Jorge López‐Castromán (ORCID: https://orcid.org/0000-0003-0618-0690)
- Lucía Albarracín-García (ORCID: https://orcid.org/0009-0009-2089-9811)
- Philippe Courtet
Institutions
- Inserm (FR)
- Université de Montpellier (FR)
- Universidade de Santiago de Compostela (ES)
- Catholic University of the Maule (CL)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Hospital Universitario Rey Juan Carlos (ES)
- Faculty of Public Health (GB)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Hospital Universitario Infanta Leonor (ES)
- Universidad Autónoma de Madrid (ES)
- Université de Nîmes (FR)
Publication Details
- Journal
- European Psychiatry
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1192/j.eurpsy.2025.10096
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00